LeMaitre Vascular Is Maintained at Outperform by Barrington Research
Barrington Maintains LeMaitre Vascular(LMAT.US) With Buy Rating, Maintains Target Price $92
Lemaitre Vascular's Growth Prospects Bolstered by Pricing Power and Strategic Expansion: A Buy Rating Review
Possible Bearish Signals With LeMaitre Vascular Insiders Disposing Stock
Is There Now An Opportunity In LeMaitre Vascular, Inc. (NASDAQ:LMAT)?
LeMaitre Vascular (NASDAQ:LMAT) Shareholders Have Earned a 25% CAGR Over the Last Five Years
LeMaitre to Participate at Upcoming Investor Conferences in September
Lake Street Maintains LeMaitre Vascular(LMAT.US) With Buy Rating, Maintains Target Price $105
Lemaitre Vascular (LMAT) Gets a Buy From Lake Street
LeMaitre Vascular CFO Retires, Joins Board of Directors
LeMaitre Vascular, Inc.: Will COnduct a Search for a Replacement CFO
LeMaitre Vascular, Inc.: Pellegrino to Remain as a Member of the Bd.
Express News | LeMaitre Vascular Inc: Announced That Joseph P. Pellegrino, Jr. Will Retire as an Employee of Co, Including as Chief Financial Officer
Express News | LeMaitre Vascular Inc - as of Aug 26, Reaffirms August 1, 2024 Financial Guidance Covering Q3 2024 and Full-Year 2024
Express News | JMP Securities Maintains Market Outperform on LeMaitre Vascular, Raises Price Target to $100
JMP Securities Maintains LeMaitre Vascular(LMAT.US) With Buy Rating, Raises Target Price to $100
Lemaitre Vascular's Strong Financial Performance and Growth Potential Warrant a Buy Rating
Investors Appear Satisfied With LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Prospects
LeMaitre Vascular's (NASDAQ:LMAT) Returns Have Hit A Wall
Robust Quarterly Result Lifted LeMaitre Vascular (LMAT) in Q2